For decades, KRAS mutations were considered undruggable — a death sentence for patients with pancreatic or lung cancers driven by this oncogene. The emergence of KRAS inhibitors has begun to upend that assumption, and new phase 1 data on a novel oral agent extend that progress to one of the mutation's most common variants, G12D, which has lagged behind G12C in therapeutic development.
GFH375 is an oral, dual on-off binding KRAS G12D inhibitor evaluated in a phase 1 trial enrolling patients with previously treated advanced solid tumors harboring KRAS G12D mutations. The trial reported encouraging objective response rates in both non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma — two of oncology's most refractory tumor types. The safety profile was characterized predominantly by low-grade treatment-related adverse events, though one treatment-related death was recorded, a finding that warrants close scrutiny as dose optimization continues in subsequent trial phases.
The significance of this result extends beyond a single compound. KRAS G12D is the most prevalent KRAS mutation in pancreatic cancer — present in roughly 40% of cases — and a common driver in colorectal and lung malignancies. Until recently, selective G12D inhibitors have lagged behind sotorasib and adagrasib, which target the G12C variant. GFH375's dual on-off binding mechanism — meaning it engages both the active GTP-bound and inactive GDP-bound conformations — could theoretically provide broader suppression of oncogenic signaling than inhibitors targeting only one state, though this mechanistic advantage requires validation in larger, randomized cohorts. As a phase 1 study, this trial was primarily powered for safety and dose-finding, not efficacy; response rates remain hypothesis-generating. Nonetheless, for patients with KRAS G12D-driven pancreatic cancer, where median survival with current therapy rarely exceeds 12 months, even early signals of activity from an orally bioavailable agent represent a meaningful development worth tracking through phase 2 and 3 evaluation.